#Clinical Trials

📰News 📈 Stocks

Eli Lilly's Orforglipron Hits Primary Endpoints in Phase 3 ACHIEVE-4 Trial

October 1, 2026 (24 days ago)

Eli Lilly's oral GLP-1 drug orforglipron demonstrates significant cardiovascular safety and efficacy in phase 3 trials, showing a 16% lower risk of…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Q32 Bio Shares Rally on Positive Week 36 SIGNAL-AA Trial Results

September 30, 2026 (24 days ago)

Q32 Bio shares gain momentum as Week 36 trial data confirms the durability of bempikibart, paving the way for optimized, less frequent…

QTTB

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eli Lilly EBGLYSS Hits Primary Endpoint in Phase 3b Dermatitis Trial

September 30, 2026 (24 days ago)

Eli Lilly reports positive Phase 3b results for EBGLYSS, showing significant skin clearance and symptom relief for patients with hand and foot…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

AbbVie Reports Positive Phase 1 Data for Metabolic Drug Candidate ABBV-295

September 30, 2026 (24 days ago)

AbbVie's ABBV-295 shows promising Phase 1 results with a long half-life, enabling potential bi-weekly dosing and strengthening the company's metabolic drug pipeline.

ABBV

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eli Lilly Retatrutide Phase 3 Trial Shows 20.8% Weight Loss in Diabetics

September 30, 2026 (25 days ago)

Eli Lilly reports positive Phase 3 data for retatrutide, with patients achieving 20.8% weight loss over 80 weeks, strengthening the company's competitive…

LLY

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Eli Lilly Orforglipron Outperforms Novo Nordisk Semaglutide in Clinical Data

September 29, 2026 (25 days ago)

Eli Lilly's orforglipron outperforms Novo Nordisk's oral semaglutide in recent clinical trials, showing superior weight loss and A1C reduction metrics that could…

LLY NVO

🌍 GLOBAL Read More →

🏢Release 📈 Stocks

Lakewood-Amedex Reports Positive Nu-3 Data for Diabetic Foot Ulcer Treatment

September 28, 2026 (26 days ago)

Lakewood-Amedex shares gain momentum as the company reports successful clinical data for its Nu-3 Bisphosphocin candidate, targeting the treatment of diabetic foot…

LABT

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Biohaven Shares Eye Gains as BHV-1530 Data Selected for ENA 2026 Presentation

September 28, 2026 (26 days ago)

Biohaven's BHV-1530 Phase 1 study data will be presented at the ENA 2026 symposium, marking a significant clinical milestone for the company's…

BHVN

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Kodiak Sciences Zenkuda Hits Primary Endpoint in Wet AMD Study

September 28, 2026 (26 days ago)

Kodiak Sciences shares rally as Zenkuda demonstrates clinical efficacy in wet AMD, establishing a potential new standard of care with durable 24-week…

KOD

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

GPN Vaccines Advances Clinical Pipeline with Gamma-PN and Gamma-SU Data

September 28, 2026 (26 days ago)

GPN Vaccines showcases clinical advancements for its Gamma-PN and Gamma-SU platforms, signaling progress in its mission to develop broadly protective vaccines for…

GPN Vaccines, Inc.

🌍 AMERICAS Read More →

🏢Release 📈 Stocks

Innovent Biologics Expands Phase 3 MarsLight-11 Study for NSCLC Treatment

September 28, 2026 (26 days ago)

Innovent Biologics broadens the scope of its Phase 3 MarsLight-11 study, targeting a wider patient population for its IBI363/TAK-928 oncology candidate to…

01801.HK

🌍 ASIA Read More →

📰News 📈 Stocks

BioNTech Shares Slip as BMO Downgrades Stock Following Clinical Setback

September 22, 2026 (32 days ago)

BMO Capital Markets downgraded BioNTech to market perform, citing a failed Phase 2 clinical trial and lowered revenue guidance, though the company…

BNTX MRNA MRK

🌍 GLOBAL Read More →